1Hartung HP, Montalban X, Sorensen PS, et al. Principl- es of a new treatment algorithm in multiple sclerosis[J]. Expert Rev Neurother, 2011,11 (3) : 351.
2Kovarik JM, Dole K, Riviere G J, et al. Ketoconazole in- creases fingolimod blood levels in a drug interaction via CYP4F2 inhibition[J]. J Clin Pharmacol, 2009,49 (2) : 212.
3Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia[J]. Expert Opin In- vestigDrugs, 2009,18(11):1 715.
4Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, pla- cebo-controlled trial[J]. J Clin Psychiatry, 2009, 70 (6) : 829.
5Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity again- st meticillin-resistant Staphylococcus aureus[J]. Drugs, 2009, 69(7): 809.
6Talbot GH, Thye D, Das A, et al. Phase 2 study of ceflaroline versus standard therapy in treatment of compli- cated skin and skin structure infections[J]. Antimicrob Agents Chemother , 2007,51 ( 10 ) : 3 612.
8Di Nisio M, Middeldorp S, Buller HR. Direct thrombin in- hibitors[J]. NEnglJMed, 2005,353(10) : 1 028.
9Stangier J, Eriksson BI, Dalai OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabagitran etexilate in healthy volunteers and patients undergoing to- tal hip replacement[J]. J Clin Pharmacol, 2005, 45 (5) : 555.
10Peterson GE, Pollom RD. Liraglutide in clinical practice : dosing, safety and efficacy[J]. Int J Clin Pract Suppl, 2010,64(167) :35.
